Not yet recruitingPhase 3NCT06833411

Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

Studying Giant cell arteritis

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Insel Gruppe AG, University Hospital Bern
Principal Investigator: Lisa Christ, Dr. med.
Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland
Intervention: Prednisone(drug)
Enrollment: 178 enrolled
Eligibility: 50 years · All sexes
Timeline: 2026 – 2032

Study locations (1)

Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06833411 on ClinicalTrials.gov

Other trials for Giant cell arteritis

Additional recruiting or active studies for the same condition.

See all trials for Giant cell arteritis →

← Back to all trials